Availability of HIV postexposure prophylaxis services in los angeles county

Clinical Infectious Diseases

Volumn 48, Issue 11, 2009, Pages 1624-1627

  Landovitz, Raphael J ^a   Combs, Kory B ^b   Currier, Judith S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTICENTER STUDY; PATIENT REFERRAL; POSTEXPOSURE PROPHYLAXIS; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH; UNITED STATES; CHEMOPROPHYLAXIS; METHODOLOGY; STATISTICS; UTILIZATION REVIEW;

CALIFORNIA; CHEMOPREVENTION; CROSS-SECTIONAL STUDIES; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS;

EID: 66949145489     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598976     Document Type: Article

References (21)

1. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA 2008;300:520-9.
2. HIV Epidemiology Program HIV/AIDS Surveillance Summary. 2008. Available at: http://publichealth.lacounty.gov/wwwfiles/ph/hae/hiv/ HIVAIDS%o20Semiannual- report-Fuly-2008.pdf. Accessed 12 December 2008.
3. Centers for Disease Control and Prevention. Antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoc-cupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. 21 January 2005. Available at: http://www.aidsinfo. nih.gov/ContentFiles/ NonOccupationalExposureGL-PDA.pdf. Accessed 20 April 2009.
4. California Task Force on Non-Occupational Post-Exposure Prophylaxis and the California Department of Health Services Office of AIDS. Offering HIV post-exposure prophylaxis (PEP) following non-occupational exposures: recommendations for health care providers in the state of California. Sacramento, CA: California Task Force on Non-Occupational Post-Exposure Prophylaxis and the California Department of Health Services Office of AIDS, 2004.
5. Low-Beer S, Weber AE, Bartholomew K, et al. A reality check: the cost of making post-exposure prophylaxis available to gay and bisexual men at high sexual risk. AIDS 2000; 14:325-6.
6. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Arch Intern Med 2004; 164:46-54.
7. Kahn JG, Pinkerton SD, Paltiel AD. Postexposure prophylaxis following HIV exposure [letter; comment]. JAMA 1999;281:1269-70.
8. Roland M, Coates T, Robillard H, et al. Demand for a non-occupational post-exposure prophylaxis telephone study referral line exceeds resources [abstract 905]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston, MA). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003.
9. Roland M, Krone M, Frances K, et al. A randomized trial of standard versus enhanced risk reduction counseling for individuals receiving post-exposure prophylaxis following sexual exposures to HIV [abstract 902]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver, CO). Alexandria, VA: Foundation for Retroviology and Human Health, 2006.
10. County of Los Angeles Public Health. HIV/AIDS semi-annual surveillance summary July 2008. Available at: http://publichealth.lacounty.gov/ wwwfiles/ph/hae/hiv/HIVAIDS%20Semiannual-report-Tuly-2008.pdf.Accessed 9 April 2009.
11. Wilper AP, Woolhandler S, Lasser KE, et al. Waits to see an emergency department physician: U.S. trends and predictors, 1997-2004. Health Aff (Millwood) 2008; 27:w84-95.
12. Lambe S, Washington DL, Fink A, et al. Waiting times in California's emergency departments. Ann Emerg Med 2003; 41:35-44.
13. County of Los Angeles Public Health. Office of AIDS Programs and Policies map reference book 2008. Available at: http://www.lapublic health.org/AIDS/ reports/OAPP%20Map%20Reference%20Book.pdf.Accessed 12 December 2008.
14. Kahn JO, Martin JN, Roland ME, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP study. J Infect Dis 2001; 183:707-14.
15. Mayer KH, Mimiaga MJ, Cohen D, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston community health center. J Acquir Immune Defic Syndr 2008; 47:494-9.
16. Shoptaw S, Rotheram-Fuller E, Landovitz R, et al. Non-occupational post exposure prophylaxis as a biobehavioral HIV prevention intervention. AIDS Care 2008; 20:376-81.
17. Martin JN, Roland ME, Neilands TB, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004; 18:787-92.
18. Schechter M, do Lago RF, Mendelsohn AB, Moreira RL, Moulton LH, Harrison LH. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophy-laxis for HIV. J Acquir Immune Defic Syndr 2004;35:519-25.
19. Wade NA, Zielinski MA, Butsashvili M, et al. Decline in perinatal HIV transmission in New York State (1997-2000). J Acquir Immune Defic Syndr 2004;36:1075-82.
20. Van damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008;359:463-72.
21. Letvin NL. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 2006; 6:930-9.